A 10% holder trimming stock on every up-day while short sellers quietly increase their position — that is the setup SNWV carries into today's earnings print.
Opaleye Management, the second-largest disclosed institutional holder with roughly 9.9% of shares, has sold on at least seven separate occasions over the past three weeks. The disposals began near $20 in late April and continued down toward $16, reducing the firm's stake by about 113,000 shares. That persistent selling pressure coincides with a stock that has dropped roughly 5% over the past month to $16.04, even as it recovered 2.6% on the week — suggesting buyers are absorbing the supply but not decisively pushing through it.
Short sellers have been moving in the same direction as Opaleye. Estimated short interest climbed 20% week-on-week to 9.4% of free float — a level that meaningfully concentrates directional risk on the downside. The one-month build is sharper still, up 27%. ORTEX's short score has tracked this momentum, rising from 73 to 78 over the past two weeks and now ranking in the top 1% of the universe. Borrow conditions are still comfortable — cost to borrow is less than 1% — so the building short position reflects genuine bearish conviction rather than a reluctant squeeze-driven unwind. Availability remains in a normal range, meaning new shorts can still be established without significant friction.
The analyst picture offers a sharp contrast. Roth Capital reiterated its Buy rating in late March, though it lowered its target to $47 from $53 — still a massive premium to where the stock trades today. The bull case rests on the 60% revenue growth SANUWAVE posted in 2024, reaching $32.6 million, and a 22% Adjusted EBITDA margin that signals the business is scaling. Bears, however, point to the same quarter that follows each year: Q1 typically suffers as patients reset annual insurance deductibles and defer procedures, hitting applicator volumes and compressing margins. Manufacturing challenges add another layer of execution risk the bears are watching.
Past earnings reactions have been uniformly negative. The March 2026 print saw the stock fall nearly 8% the following day and extend losses to roughly 9% over the subsequent five sessions. The release before that produced a 7% one-day drop and a 15% five-day slide. Today's print is therefore a direct test of whether the 2024 revenue momentum has survived the seasonal Q1 headwind — and whether management can offer enough confidence on margins and manufacturing to interrupt what has been a consistent post-earnings pattern of selling.
See the live data behind this article on ORTEX.
Open SNWV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
